/

AKTX

Akari Therapeutics PlcClosed

7.90−0.64 −7.49%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

8.33

Prev close

8.54

Day range

7.908.70

52-week range

3.0236.76

Volume

18.52K0.30×

Mkt cap

18.05M

P/E ttm

—

Fwd P/E

-0.91

EPS ttm

0.000000

Div yield

0.00%

Earnings

—

From 52w high

−78.51%

Price Chart

Yahoo Finance · delayed

AKTXOct 13, 2026O 8.33H 8.70L 7.90C 7.90−0.64 (−7.49%)Vol 18.50K

SMA 509.05
SMA 2009.24

1Y change −79.03% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

AKTX Akari Therapeutics Plc · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −5.84%
1 month: −30.09%
3 months: −41.13%
6 months: +70.63%
Year to date: −31.66%
1 year: −79.03%

Valuation & ownership

Market cap: 18.05M
Enterprise value: 8.38M
P/E (ttm): —
Forward P/E: -0.91
PEG ratio: —
Price / book: 0.74
Price / sales (ttm): —
EV / EBITDA: —
EPS (ttm): 0.000000
EPS (forward): -8.65
Beta (5y monthly): 1.44
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 2.29M
Float: 1.16M
Short % of float: 1.00%
Short ratio (days): 0.18
Held by insiders: 13.25%
Held by institutions: 10.52%
Avg volume (3m): 61.98K
50-day average: 9.04
200-day average: 9.25
52-week change: −79.03%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 38.1
vs 50-day SMA: −12.70%
vs 200-day SMA: −14.47%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 12.44%
Realised vol (20d, ann.): 71.7%
From 52-week high: −80.07%
From 52-week low: +162.02%

ANR

Analyst Consensus

3 analysts

Consensus

—

Mean target

25.50

+222.78% implied

Low 19.50Median 27.00High 30.00

Recommendation trend

Now3 / 0 / 0
1m ago2 / 0 / 0

DES

About Akari Therapeutics Plc

Yahoo Finance profile

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.

Sector: Healthcare
Industry: Biotechnology
Employees: 5
Headquarters: Tampa, FL, United States
Website: akaritx.com
Officers: Mr. Abizer Gaslightwala CEO, President & Director
Mr. Kameel D. Farag Interim Chief Financial Officer
Dr. Satyajit Mitra Ph.D. Executive Director & Head of Oncology

SEAS

Seasonality · AKTX

2014–2026 · monthly returns

Strongest month Aug +23.13%Weakest month Feb −18.84%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-18.7	0.4	-45.4	4.9	204.3	-37.6	-23.3	32.7	-10.8	-15.1			−31.7%
2025	-10.7	-20.2	42.5	16.1	-6.2	-13.3	-12.0	-26.2	32.9	-25.7	-35.2	-40.5	−76.3%
2024	-16.0	-10.3	-20.6	-17.4	11.3	57.5	43.3	-1.0	-23.0	-18.6	-49.6	0.8	−60.9%
2023	-0.6	-26.1	-47.2	-0.5	-2.2	-4.0	47.1	-37.0	25.4	-13.7	-13.5	5.8	−66.8%
2022	-8.7	-1.5	-11.1	-0.8	-1.7	-14.5	14.0	4.4	-47.1	-26.0	18.7	-15.0	−68.7%
2021	36.8	32.4	-21.2	-22.0	-12.9	-3.6	-6.4	13.6	-11.4	1.8	-1.8	-8.0	−18.9%
2020	2.9	2.2	-21.2	32.4	6.3	6.9	-7.8	-14.4	1.2	-13.8	6.7	15.6	+5.7%
2019	28.0	-10.0	97.8	0.0	-46.9	6.3	-6.9	10.6	-17.8	11.1	8.4	-15.0	+11.5%
2018	-33.9	-31.8	-6.7	4.9	-3.7	6.0	-1.5	-2.1	36.2	-29.7	-0.6	-12.3	−63.7%
2017	13.6	-18.6	70.0	35.4	-59.1	-24.8	0.9	-23.7	73.0	-30.1	13.3	-10.9	−38.5%
2016	-4.6	-30.2	44.9	22.9	-12.2	-10.7	-31.1	1.7	-10.0	11.0	-24.3	-1.5	−51.4%
2015	20.8	-84.5	-15.6	-1.3	-41.6	32.4	-1.7	347.4	-5.9	-20.4	1.6	-25.3	−69.8%
2014		-27.5	0.6	-6.0	-16.4	21.6	-8.7	4.2	3.4	-3.0	-10.1	-9.8	−46.1%

INSD

Insider Activity · AKTX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Aug 16, 2026	Farag Kameel DChief Financial Officer	Stock Award(Grant) at price 7.52 per share.	1.7K	$12.99K
Jul 15, 2026	Farag Kameel DChief Financial Officer	Stock Award(Grant) at price 11.50 per share.	1.1K	$12.99K
Jul 6, 2026	Patel Samir RashmikantDirector and Beneficial Owner of more than 10% of a Class of Security	Conversion of Exercise of derivative security at price 0.00 - 8.00 per share.	22.5K	$9.68K
Jun 23, 2026	Farag Kameel DChief Financial Officer	Stock Award(Grant) at price 9.32 - 10.76 per share.	18.8K	$199.60K
Oct 30, 2025	Farag Kameel DChief Financial Officer	Stock Award(Grant) at price 0.75 per share.	58.6K	$43.96K
Oct 21, 2025	Farag Kameel DChief Financial Officer	Stock Award(Grant) at price 0.74 per share.	6.3K	$4.64K
Aug 24, 2025	Gaslightwala AbizerChief Executive Officer	Purchase at price 0.90 - 0.94 per share.	21K	$19.54K
Jun 23, 2025	Gaslightwala AbizerChief Executive Officer	Purchase at price 1.15 - 1.16 per share.	6.1K	$7.12K
Jun 19, 2025	Gaslightwala AbizerChief Executive Officer	Purchase at price 1.20 per share.	10K	$12.00K
Jun 16, 2025	Gaslightwala AbizerChief Executive Officer	Purchase at price 1.20 per share.	15K	$18.00K
Jun 12, 2025	Gaslightwala AbizerChief Executive Officer	Stock Award(Grant) at price 1.19 - 1.23 per share.	45K	$54.35K
Jun 9, 2025	Gaslightwala AbizerChief Executive Officer	Stock Award(Grant) at price 1.27 per share.	20K	$25.40K
Mar 5, 2025	Neal James RDirector	Stock Award(Grant) at price 1.12 per share.	4.5K	$5.00K
Mar 5, 2025	Huh HoyoungDirector and Beneficial Owner of more than 10% of a Class of Security	Stock Award(Grant) at price 1.12 per share.	892.9K	$1.00M
Mar 5, 2025	Bazemore Robert BDirector	Stock Award(Grant) at price 1.12 per share.	44.6K	$50.00K
Mar 5, 2025	Prudo-Chlebosz RaymondDirector	Stock Award(Grant) at price 1.12 per share.	446.4K	$500.00K
Mar 5, 2025	Patel Samir RashmikantDirector	Stock Award(Grant) at price 1.12 per share.	406.3K	$455.00K
Mar 5, 2025	Patel Sandip IDirector	Stock Award(Grant) at price 1.12 per share.	44.6K	$50.00K
Mar 5, 2025	Gaslightwala AbizerDirector	Stock Award(Grant) at price 1.12 per share.	133.9K	$150.00K
Jan 9, 2025	Hombeck TorstenChief Financial Officer	Stock Award(Grant) at price 1.22 per share.	200	$244

AKTX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

AKTX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Akari Therapeutics Plc

Seasonality · AKTX

Insider Activity · AKTX

Congress Trades · AKTX

Investors Holding AKTX

Investors Holding AKTX

Congress Trades · AKTX

Insider Activity · AKTX

Seasonality · AKTX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Akari Therapeutics Plc

Financial Snapshot

Earnings & Dividends

News